Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

1.73
-0.3150-15.44%
Post-market: 1.740.0150+0.87%19:10 EDT
Volume:2.69M
Turnover:4.61M
Market Cap:108.61M
PE:-1.45
High:1.82
Open:1.79
Low:1.58
Close:2.04
52wk High:3.82
52wk Low:1.23
Shares:62.96M
Float Shares:21.07M
Volume Ratio:2.16
T/O Rate:12.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1933
EPS(LYR):-1.0000
ROE:-140.51%
ROA:-69.75%
PB:4.04
PE(LYR):-1.72

Loading ...

Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Apr 02

Connect Biopharma director James Huang acquires $4 million common shares

Reuters
·
Apr 02

Connect Biopharma Holdings Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 01

Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate

Benzinga Earnings
·
Apr 01

Connect Biopharma FY25 net loss widens to $55.5 million; cash, investments fall to $44 million

Reuters
·
Apr 01

Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Dow Jones
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Mar 31

Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Mar 31

Connect Biopharma Shares Decline on Private Placement

Dow Jones
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)

TIPRANKS
·
Mar 30

Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd

Reuters
·
Mar 30

BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results

TIPRANKS
·
Mar 30

BUZZ-Connect Biopharma rises as eczema drug shows lasting benefit in China study

Reuters
·
Mar 30

Connect Biopharma says rademikibart hits EASI-75 in 96.6% in Phase 3 AD trial

Reuters
·
Mar 30

Connect Biopharma says Phase 1 IV rademikibart trial shows rapid FEV1 improvement in asthma, COPD

Reuters
·
Mar 30

Press Release: Connect Biopharma Announces $20.2 Million Private Placement Financing

Dow Jones
·
Mar 30

Connect Biopharma Holdings Ltd - Rademikibart Achieves Rapid, Durable Efficacy in Phase 3 Atopic Dermatitis Study Through 52 Weeks

THOMSON REUTERS
·
Mar 30